Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure

被引:36
作者
Shah, Nimit C.
Pringle, Stuart D.
Donnan, Peter T.
Struthers, Allan D. [1 ]
机构
[1] Ninewells Hosp, Div Med & Therapeut, Dundee DD1 9SY, Scotland
[2] Ninewells Hosp, Dundee, Scotland
[3] Ninewells Hosp, Dept Cardiol, Dundee DD1 9SY, Scotland
关键词
arrhythmias; cardiac fibrosis; endothelium; renin-angiotensin-aldosterone system; spironolactone;
D O I
10.1097/HJH.0b013e3282e9a72d
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Objectives To examine whether endogenous aldosterone can cause either arrhythmias (and some of their underlying mechanisms) or endothelial dysfunction in patients with coronary artery disease (CAD) but without heart failure. Background Aldosterone blockade has been shown to reduce the incidence of sudden death in patients with heart failure. This could be caused by a reduction in arrhythmias or in coronary events. Whether either effect also occurs in other cardiac patients without heart failure is currently unknown. Method We performed a randomized, placebo-controlled, double-blind crossover study on 98 patients with CAD but without heart failure on standard therapy, comparing 12.550-mg/day spironolactone (3 months) with placebo. Endothelial function was assessed by bilateral forearm venous occlusion plethysmography. Ventricular extrasystoles, procollagen III N-terminal peptide (PIIINP) and QT interval length were used to represent arrhythmias and their determinants. Results Spironolactone produced a highly significant 75% reduction in ventricular extrasystoles (median 192, range 48-744) on placebo compared with spironolactone (median 48, range 19.2-288, P<0.003). Spironolactone also decreased the QT interval from a mean of 440 28 to a mean of 425 25 (P< 0.001) and a collagen marker (PIIINP) from a mean of 3.6 +/- 0.9 to a mean of 3.0 +/- 0.8(P< 0.001), but did not significantly change endothelial dysfunction or heart rate variability. onclusion These results suggest that despite conventional therapy, endogenous aldosterone can be an arrhythmogenic influence in patients with CAD, but without heart failure. The possible mechanisms are that aldosterone promotes myocardial fibrosis and lengthens the QT(c) interval as well as decreasing potassium in CAD patients, without heart failure.
引用
收藏
页码:2345 / 2351
页数:7
相关论文
共 27 条
[1]   Diurnal, weekly and seasonal variation of sudden death -: Population-based analysis of 24 061 consecutive cases [J].
Arntz, HR ;
Willich, SN ;
Schreiber, C ;
Brüggemann, T ;
Stern, R ;
Schultheiss, HP .
EUROPEAN HEART JOURNAL, 2000, 21 (04) :315-320
[2]  
ARORA R B, 1962, Life Sci (1962), V1, P215, DOI 10.1016/0024-3205(62)90021-8
[3]   EFFECTS OF ADDING SPIRONOLACTONE TO AN ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR IN CHRONIC CONGESTIVE-HEART-FAILURE SECONDARY TO CORONARY-ARTERY DISEASE [J].
BARR, CS ;
LANG, CC ;
HANSON, J ;
ARNOTT, M ;
KENNEDY, N ;
STRUTHERS, AD .
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 76 (17) :1259-1265
[4]   MEASURING FOREARM BLOOD-FLOW AND INTERPRETING THE RESPONSES TO DRUGS AND MEDIATORS [J].
BENJAMIN, N ;
CALVER, A ;
COLLIER, J ;
ROBINSON, B ;
VALLANCE, P ;
WEBB, D .
HYPERTENSION, 1995, 25 (05) :918-923
[5]   High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction [J].
Beygui, Farzin ;
Collet, Jean-Philippe ;
Benoliel, Jean-Jacques ;
Vignolles, Nicolas ;
Dumaine, Raphaelle ;
Barthelemy, Olivier ;
Montalescot, Gilles .
CIRCULATION, 2006, 114 (24) :2604-2610
[6]  
Camm AJ, 1996, CIRCULATION, V93, P1043
[7]   C-type natriuretic peptide - An endogenous inhibitor of vascular angiotensin-converting enzyme activity [J].
Davidson, NC ;
Barr, CS ;
Struthers, AD .
CIRCULATION, 1996, 93 (06) :1155-1159
[8]   Spironolactone impairs endothelial function and heart rate variability in patients with Type 2 diabetes [J].
Davies, JI ;
Band, M ;
Morris, A ;
Struthers, AD .
DIABETOLOGIA, 2004, 47 (10) :1687-1694
[9]   Ventricular arrhythmias during 24-h ambulatory ECG recording:: incidence, risk factors and prognosis in men with and without a history of cardiovascular disease [J].
Engström, G ;
Hedblad, B ;
Janzon, L ;
Juul-Möller, S .
JOURNAL OF INTERNAL MEDICINE, 1999, 246 (04) :363-372
[10]   Allopurinol improves endothelial dysfunction in chronic heart failure [J].
Farquharson, CA ;
Butler, R ;
Hill, A ;
Belch, JJF ;
Struthers, AD .
CIRCULATION, 2002, 106 (02) :221-226